Literature DB >> 15765143

Licking latency with licorice.

Jeffrey I Cohen1.   

Abstract

Numerous viruses cause latent infections in humans, and reactivation often results in pain and suffering. While vaccines for several of these viruses are available or currently being studied in clinical trials, and antiviral therapies have been successful in preventing or treating active infection, therapy to eradicate latent infection has lagged behind. A new study reported in this issue of the JCI shows that treatment of cells latently infected with Kaposi sarcoma-associated herpesvirus (KSHV) with glycyrrhizic acid, a component of licorice, reduces synthesis of a viral latency protein and induces apoptosis of infected cells. This finding suggests a novel way to interrupt latency.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15765143      PMCID: PMC1052015          DOI: 10.1172/JCI24507

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  19 in total

1.  Role of vascular endothelial growth factor/vascular permeability factor in the pathogenesis of Kaposi's sarcoma-associated herpesvirus-infected primary effusion lymphomas.

Authors:  Y Aoki; G Tosato
Journal:  Blood       Date:  1999-12-15       Impact factor: 22.113

2.  Differential viral protein expression in Kaposi's sarcoma-associated herpesvirus-infected diseases: Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

Authors:  C Parravicini; B Chandran; M Corbellino; E Berti; M Paulli; P S Moore; Y Chang
Journal:  Am J Pathol       Date:  2000-03       Impact factor: 4.307

3.  Human interleukin-6 is in vivo an autocrine growth factor for human herpesvirus-8-infected malignant B lymphocytes.

Authors:  A Foussat; J Wijdenes; L Bouchet; G Gaidano; F Neipel; K Balabanian; P Galanaud; J Couderc; D Emilie
Journal:  Eur Cytokine Netw       Date:  1999-12       Impact factor: 2.737

Review 4.  The pharmacokinetics of glycyrrhizic acid evaluated by physiologically based pharmacokinetic modeling.

Authors:  B Ploeger; T Mensinga; A Sips; W Seinen; J Meulenbelt; J DeJongh
Journal:  Drug Metab Rev       Date:  2001-05       Impact factor: 4.518

Review 5.  Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.

Authors:  S J Mentzer; S P Perrine; D V Faller
Journal:  Transpl Infect Dis       Date:  2001-09       Impact factor: 2.228

6.  Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells.

Authors:  S A Keller; E J Schattner; E Cesarman
Journal:  Blood       Date:  2000-10-01       Impact factor: 22.113

7.  Epstein-Barr virus-targeted therapy for AIDS-related primary lymphoma of the central nervous system.

Authors:  K S Slobod; G H Taylor; J T Sandlund; P Furth; K J Helton; J W Sixbey
Journal:  Lancet       Date:  2000-10-28       Impact factor: 79.321

8.  Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease.

Authors:  H Katano; Y Sato; T Kurata; S Mori; T Sata
Journal:  Virology       Date:  2000-04-10       Impact factor: 3.616

9.  Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas.

Authors:  Wen-hai Feng; Gregory Hong; Henri-Jacques Delecluse; Shannon C Kenney
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Inhibition of STAT3 signaling induces apoptosis and decreases survivin expression in primary effusion lymphoma.

Authors:  Yoshiyasu Aoki; Gerald M Feldman; Giovanna Tosato
Journal:  Blood       Date:  2002-10-03       Impact factor: 22.113

View more
  10 in total

1.  Mechanism of glycyrrhizic acid inhibition of Kaposi's sarcoma-associated herpesvirus: disruption of CTCF-cohesin-mediated RNA polymerase II pausing and sister chromatid cohesion.

Authors:  Hyojeung Kang; Paul M Lieberman
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

2.  Anti-inflammatory Activity of Magnesium Isoglycyrrhizinate Through Inhibition of Phospholipase A2/Arachidonic Acid Pathway.

Authors:  Chunfeng Xie; Xiaoting Li; Jieshu Wu; Zhaofeng Liang; Feifei Deng; Wei Xie; Mingming Zhu; Jianyun Zhu; Weiwei Zhu; Shanshan Geng; Caiyun Zhong
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

3.  Kaposi's sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment through an interleukin-6-dependent mechanism: a new paradigm for viral immune evasion.

Authors:  L M Butler; H C Jeffery; R L Wheat; P C Rae; K Townsend; K R Alkharsah; T F Schulz; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2011-05-04       Impact factor: 5.103

4.  18β-Glycyrrhetinic acid inhibits methicillin-resistant Staphylococcus aureus survival and attenuates virulence gene expression.

Authors:  Danyelle R Long; Julia Mead; Jay M Hendricks; Michele E Hardy; Jovanka M Voyich
Journal:  Antimicrob Agents Chemother       Date:  2012-10-31       Impact factor: 5.191

5.  β-HHVs and HHV-8 in Lymphoproliferative Disorders.

Authors:  C Quadrelli; P Barozzi; G Riva; D Vallerini; E Zanetti; L Potenza; F Forghieri; M Luppi
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-10-24       Impact factor: 2.576

6.  The Effect of Aqueous Extract of Glycyrrhiza glabra on Herpes Simplex Virus 1.

Authors:  Masoud Sabouri Ghannad; Avid Mohammadi; Sohayla Safiallahy; Javad Faradmal; Mona Azizi; Zohreh Ahmadvand
Journal:  Jundishapur J Microbiol       Date:  2014-07-01       Impact factor: 0.747

7.  Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency.

Authors:  Gretchen L Bentz; Angela J Lowrey; Dustin C Horne; Vy Nguyen; Austin R Satterfield; Tabithia D Ross; Abigail E Harrod; Olga N Uchakina; Robert J McKallip
Journal:  PLoS One       Date:  2019-05-24       Impact factor: 3.240

Review 8.  Glycyrrhizic Acid: A Natural Plant Ingredient as a Drug Candidate to Treat COVID-19.

Authors:  Zhong Sun; Guozhong He; Ninghao Huang; Karuppiah Thilakavathy; Jonathan Chee Woei Lim; S Suresh Kumar; Chenglong Xiong
Journal:  Front Pharmacol       Date:  2021-07-09       Impact factor: 5.810

Review 9.  Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds.

Authors:  Marjan Nassiri Asl; Hossein Hosseinzadeh
Journal:  Phytother Res       Date:  2008-06       Impact factor: 5.878

Review 10.  Antiviral effects of Glycyrrhiza species.

Authors:  Cristina Fiore; Michael Eisenhut; Rea Krausse; Eugenio Ragazzi; Donatella Pellati; Decio Armanini; Jens Bielenberg
Journal:  Phytother Res       Date:  2008-02       Impact factor: 5.878

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.